Jazz Pharmaceuticals, Novartis and Pfizer side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | Jazz Pharmaceuticals | Novartis | Pfizer |
|---|---|---|---|
| Phase 1 | 38% | Novartis: 16 of its 77 programs at phase 1
and 11 more — sign in to see them all | Pfizer: 42 of its 91 programs at phase 1
and 37 more — sign in to see them all |
| Phase 2 | Jazz Pharmaceuticals: 2 of its 8 programs at phase 2
| Novartis: 35 of its 77 programs at phase 2
and 30 more — sign in to see them all | Pfizer: 10 of its 91 programs at phase 2
and 5 more — sign in to see them all |
| Phase 3 | Jazz Pharmaceuticals: 1 of its 8 programs at phase 3
| Novartis: 18 of its 77 programs at phase 3
and 13 more — sign in to see them all | Pfizer: 31 of its 91 programs at phase 3
and 26 more — sign in to see them all |
| Approved, new studies | Jazz Pharmaceuticals: 2 of its 8 programs at approved, new studies
| Novartis: 8 of its 77 programs at approved, new studies
and 3 more — sign in to see them all | Pfizer: 8 of its 91 programs at approved, new studies
and 3 more — sign in to see them all |
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jazz Pharmaceuticals5 readouts · 1 phase 3 | Jazz Pharmaceuticals, Nov ’26: 1 program whose next study reaches primary completion
| Jazz Pharmaceuticals, Dec ’26: 1 program whose next study reaches primary completion
| · | Jazz Pharmaceuticals, Feb ’27: 1 program whose next study reaches primary completion
| Jazz Pharmaceuticals, Mar ’27: 1 program whose next study reaches primary completion
| · | · | · | · | Jazz Pharmaceuticals, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| · | · |
| Novartis27 readouts · 5 phase 3 | Novartis, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3
| Novartis, Dec ’26: 5 programs whose next study reaches primary completion
| Novartis, Jan ’27: 3 programs whose next study reaches primary completion, 1 in phase 3
| Novartis, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3
| Novartis, Mar ’27: 3 programs whose next study reaches primary completion, 1 in phase 3
| Novartis, Apr ’27: 4 programs whose next study reaches primary completion
| Novartis, May ’27: 2 programs whose next study reaches primary completion
| · | Novartis, Jul ’27: 3 programs whose next study reaches primary completion
| Novartis, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3
| Novartis, Sep ’27: 1 program whose next study reaches primary completion
| · |
| Pfizer37 readouts · 10 phase 3 | Pfizer, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3
| Pfizer, Dec ’26: 8 programs whose next study reaches primary completion, 2 in phase 3
and 3 more — sign in to see them all | Pfizer, Jan ’27: 3 programs whose next study reaches primary completion, 1 in phase 3
| Pfizer, Feb ’27: 5 programs whose next study reaches primary completion, 1 in phase 3
| Pfizer, Mar ’27: 3 programs whose next study reaches primary completion
| Pfizer, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3
| Pfizer, May ’27: 2 programs whose next study reaches primary completion, 1 in phase 3
| Pfizer, Jun ’27: 3 programs whose next study reaches primary completion
| · | Pfizer, Aug ’27: 4 programs whose next study reaches primary completion, 1 in phase 3
| Pfizer, Sep ’27: 3 programs whose next study reaches primary completion, 2 in phase 3
| Pfizer, Oct ’27: 3 programs whose next study reaches primary completion
|
Changed in the last 90 days
Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
Jazz Pharmaceuticals
New programs 1
- JZP269phase 1 · first study · Sep 4
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 3
- lurbinectedinphase 2 · Jan 2028 → Aug 2029 (+18 mo) · moved Nov 6 · NCT07459634
- JZP047phase 1 · Jul 2026 → Nov 2026 (+5 mo) · moved Oct 23 · NCT07377539
- zeltipronephase 1 · Jul 2026 → Mar 2027 (+9 mo) · moved Oct 23 · NCT04541082
Novartis
New programs 5
- pacibekitugphase 3 · first study · Nov 9 · Myocardial Infarction
- DKB903phase 1 · first study · Nov 2 · Arthritis, Rheumatoid
- TRB191phase 1 · first study · Oct 26 · Small Cell Lung Carcinoma
- XEP527phase 1 · first study · Oct 26 · Schizophrenia
- YMI024phase 2 · first study · Sep 15 · Coronary Artery Disease
Reached a new phase 1
- Oligonucleotides, Antisensephase 2 · Oct 5 · Supranuclear Palsy, Progressive
Study stopped 5
- Lutetium-177phase 1 · terminated Nov 17“Sponsor decision and not a consequence of any safety concerns.” · NCT06379217
- pelacarsenphase 3 · terminated Nov 10“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT05900141
- opnurasibphase 3 · terminated Nov 6“Business reasons and not based on any safety concerns.” · NCT05132075
- ianalumabphase 2 · withdrawn Oct 15“The study was discontinued due to evolving scientific \& feasibility considerations that could adversely af…” · NCT07039422
- pelacarsenphase 3 · withdrawn Oct 14“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT07625306
Primary completion later 5
- pelabresibphase 3 · Jun 2027 → Dec 2029 (+31 mo) · moved Nov 12 · NCT06401356
- inclisiranapproved, new study · Feb 2027 → Feb 2028 (+12 mo) · moved Oct 30 · NCT07684469
- pelacarsenphase 3 · Dec 2028 → Jan 2029 (+2 mo) · moved Oct 14 · NCT07625306
- Alpelisibphase 2 · Aug 2028 → Jan 2029 (+6 mo) · moved Oct 5 · NCT06997588
- ianalumabphase 3 · Apr 2030 → Apr 2034 (+48 mo) · moved Oct 1 · NCT06133972
Pfizer
New programs 6
- PF-08166744phase 1 · first study · Nov 5
- PF-08161842phase 1 · first study · Oct 20 · Alzheimer Disease
- PF-08165784phase 1 · first study · Oct 20 · Breast Neoplasms
- PF-08098488phase 1 · first study · Oct 12 · Esophageal Neoplasms
- PF-08656795phase 1 · first study · Oct 9 · Obesity
- PG4 Multivalent Vaccinephase 3 · first study · Aug 26 · Pneumococcal Infections
Reached a new phase 0
None
Study stopped 3
- PF-07868489phase 2 · terminated Nov 2 · none of its studies left running“The study terminated due to a business decision and was not based on any safety and/or efficacy concerns.” · NCT07073820
- vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. T…” · NCT05573555
- vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 11 participants enrolled in Ph1b. Th…” · NCT06125522
Primary completion later 6
- mevrometostatphase 3 · Dec 2026 → Feb 2027 (+2 mo) · moved Oct 30 · NCT06551324
- mevrometostatphase 3 · Dec 2026 → Sep 2027 (+10 mo) · moved Oct 30 · NCT06629779
- PF-07328948phase 2 · Nov 2027 → May 2028 (+6 mo) · moved Oct 23 · NCT06991257
- rimegepantphase 3 · Aug 2028 → Feb 2030 (+18 mo) · moved Oct 23 · NCT06616194
- atirmociclibphase 2 · Sep 2026 → Oct 2029 (+36 mo) · moved Oct 21 · NCT04557449
- tivunatamigphase 3 · Jul 2031 → Jan 2032 (+6 mo) · moved Sep 28 · NCT07392892
Where they overlap
Conditions where at least two of them have programs: 26 in all, the first 12 here. A program counts in each condition its studies name most.
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
| Target | Jazz Pharmaceuticals | Novartis | Pfizer |
|---|---|---|---|
| ERBB2 | zanidatamabrule | Gallium-68, Lutetium-177 | disitamab vedotin, tucatinibrule |
| CD3E | – | Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565, blinatumomabrule | elranatamabrule |
| IL13 | – | GHZ339 | tilrekimig, ompekimig |
| CDK2 | – | CDK2 Inhibitor ECI830 | tegtociclib |
| EZH2 | – | tulmimetostat | mevrometostat |
| JAK1 | – | ruxolitinibrule | abrocitinibrule |
| JAK3 | – | ruxolitinibrule | ritlecitinibrule |
| KRAS | – | opnurasibrule | Pan-KRAS Inhibitor PF-07985045rule |
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
- Programs a company names but has not registered are counted apart (Novartis: 7, Pfizer: 9).